Creating Memory: Vaccines & Immunity

We talk with Dr. Daniel Malouli, an assistant professor at the Vaccine and Gene Therapy Institute at the Oregon Health and Science University, OR, who studies how virus-host interactions modulate CMV infection and pathogenesis as well as determine the safety and efficacy of CMV-based vaccine vectors.  

We talk with Dr. Sumanta Naik, a staff scientist in the Department of Molecular Microbiology at Washington University School of Medicine, who is investigating the role of IRGM1 in type I interferon and B cell responses following vaccination and tuberculosis infection. 

We talk with Dr. Mario Feldman, Professor of Microbiology at Washington University School of Medicine in St. Louis, MO who studies the pathogenesis of Acinetobacter and the biogenesis of bacterial extracellular vesicles.

We talk with Dr. Daniel Hoft, Director of the Division of Infectious Diseases, Allergy & Immunology and the Center for Vaccine Development at Saint Louis University School of Medicine in St. Louis, MO who studies the development of T-cell targeting vaccines against mucosally-invasive intracellular pathogens such as tuberculosis and influenza.

We talk with Dr. Michela Locci, Associate Professor of Microbiology at the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA who studies how T follicular helper cells promote optimal germinal cell reactions and antibody responses following vaccination.

We talk with Dr. Namit Chaudhary, a postdoctoral researcher in the Department of Immunology & Microbiology at The Scripps Research Institute, CA, who develops new technologies to generate a safe and effective single-shot lipid nanoparticle-based HIV vaccine. 

We talk with Dr. Zhouming Liu, an assistant professor of Molecular Microbiology at Washington University School of Medicine, MO, who studies mechanisms of La Cross virus entry and monoclonal antibody–mediated inhibition of infection.

We talk with Dr. Annie Elong Ngono, a research instructor in the Center for Vaccine Innovation at the La Jolla Institute for Immunology, CA, who studies the role of T cells in vaccine-mediated protection and neurological disease following flavivirus infection.

We talk with Dr. Anass Abbad, a postdoctoral fellow in the Department of Microbiology at the Icahn School of Medicine Mount Sinai, NY who studies humoral immune responses and virus-host receptor interactions to design next generation pandemic virus vaccines.

We talk with Dr. Sandhya Bangaru, a staff scientist in the Department of Integrative Structural and Computational Biology at The Scripps Research Institute, CA who uses advances in cryo-EM to understand antibody epitopes important for their antiviral protective activity and their pathogenic activity in allergic diseases.

We talk with Dr. Florian Krammer, the endowed Mount Sinai Professor of Vaccinology at the Icahn School of Medicine, New York, NY and Director of the Ludwig Boltzmann Institute for Science Communication and Pandemic Preparedness at the Medical University of Vienna, Austria, who studies the B cell response in the context of natural infection to better understand how to design broadly protective and durable vaccines.

We talk with Dr. John Gridley, a postdoctoral fellow in the Vaccinology Training Program at Emory University, GA, who uses a hepatitis C virus-related rodent hepacivirus model to identify correlates of protective immunity for HCV and the role of inducible Hepatic-Associated Lymphoid Tissue (iHALT) in the induction of this immune response.

We talk with Dr. Sandro Galea, Dean and Professor of the School of Public Health at Washington University in St. Louis, who uses population based sciences to promote health locally and globally.

We talk with Dr. Hedda Wardemann, Division Head of B Cell Immunology at the German Cancer Research Center and Professor at the Medical Faculty of the University of Heidelberg in Heidelberg, Germany, who studies B cell responses in the context of infectious disease and cancer. . 

We talk with Dr. Emanuele Andreano, Head of Serology and Immunology at Fondazione Biotecnopolo di Siena, Italy, who combines immunology, structural biology and artificial intelligence to rapidly develop novel monoclonal antibodies therapies and antiviral vaccine targets.

We talk with Dr. Daniel Wrapp, Assistant Professor Assistant Professor at the Duke Human Vaccine Institute at Duke University School of Medicine, NC, who uses structure-based design to develop novel therapeutic interventions against viruses.

We talk with Dr. Paeton Wantuch, a Staff Scientist in the Department of Pediatrics at Washington University School of Medicine, MO, who uses animal models to understand correlates of protection for vaccines against Klebsiella pneumoniae.

We talk with Dr. Cassie Simonich, Pediatric Infectious Diseases Fellow at the University of Washington, WA, who uses RSV pseudoviruses and deep mutational scanning approaches to define the evolution of the RSV fusion protein to escape natural or vaccine-induced immunity and monoclonal antibody treatments.

We talk with Dr. Alba Grifoni, Research Assistant Professor scholar in the Center for Vaccine Innovation at the La Jolla Institute for Immunology, CA, who uses bioinformatic analyses and immune focusing approaches to improve protective T cell responses induced by vaccines.

We talk with Dr. Alexander Cohen, Postdoctoral Scholar in the Division of Biology and Biological Engineering at the California Institute of Technology, CA, who uses immune focusing approaches to design vaccines that generate antibodies against conserved epitopes on viral antigens.

We talk with Dr. Hanover Matz, Postdoctoral Research Associate in Pathology and Immunology at Washington University School of Medicine, MO, who uses human vaccine studies as well as comparisons to other vertebrate immune systems to understand how adaptive immunity has evolved and how we can use that information to generate more effective vaccines.

We talk with Dr. Seth Zost, Research Instructor in the Vanderbilt Vaccine Center at Vanderbilt University Medical Center, TN, who is developing new approaches to define how antibody responses to SARS-CoV-2 and influenza viruses shape the antigenic evolution of these viruses.

We talk with Dr. Brett Case, Instructor of Infectious Diseases at Washington University School of Medicine, MO, who studies how to generate cross-protective and sterilizing mucosal immunity following vaccination.

We talk with Dr. Christina Stallings, Professor of Molecular Microbiology at Washington University School of Medicine, MO, who studies host molecules important for mycobacterium tuberculosis pathogenesis to develop new therapies to treat mycobacterium infection and disease. 

We talk with Dr. Robert Seder, Chief of the Cellular Immunology Section of the Vaccine Research Center in Bethesda, MD, who studies how changing the route of vaccination can improve immunity and protection against pathogens.

We talk with Dr. Nardhy Gomez-Lopez, a professor at Washington University School of Medicine in St. Louis, MO, who studies the immunology of pregnancy and birth to identify biomarkers that may predict adverse outcomes.

We talk with Dr. Gabriel Victora, an associate professor and HHMI investigator at The Rockefeller University in NY, NY, who studies how antibodies are generated in response to infection and immunization through the evolutionary process of affinity maturation in germinal centers.

We talk with Dr. Helen Chu, a physician and professor at the University of Washington in Seattle, WA, who studies the transmission of respiratory viruses in the community and correlates of immune protection induced by maternal vaccines against these viruses.